Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 5Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Plasma cell 1

Conditions

Breast Neoplasms 2Recurrence 1Multiple Myeloma 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × tetrathiomolybdate × Clear all
NCT00195091 2025-05-16

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
16 enrolled 5 charts
Breast

Breast Neoplasms

NCT00674557 2013-07-10

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
111 enrolled
Breast

Breast Neoplasms

NCT00352742 2008-10-28

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

Attenuon

Phase 1/2 Terminated
46 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡